Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine_ an interim analysis of a randomised controlled phase 3 trial in Russia – Société de Pédiatrie de l'Ouest

You are currently viewing Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine_ an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine_ an interim analysis of a randomised controlled phase 3 trial in Russia

Post author:Admin
Post published:3 février 2021
Post category:COVID 19

Safety-and-efficacy-of-an-rAd26-and-rAd5-vector-based-heterologous-prime-boost-COVID-19-vaccine_-an-interim-analysis-of-a-randomised-controlled-phase-3-trial-in-Russia Télécharger